Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Musculoskeletal Diseases AND Arthritis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    638 result(s) found for: Musculoskeletal Diseases AND Arthritis. Displaying page 1 of 32.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-019262-86 Sponsor Protocol Number: LTS11210 Start Date*: 2011-06-22
    Sponsor Name:sanofi-aventis Recherche & Développement
    Full Title: Estudio de extensión multicéntrico no controlado que evalúa la eficacia y seguridad de SAR153191 junto con Fármacos Anti-Reumáticos Modificadores de la Enfermedad (FARMEs) en pacientes con Artritis...
    Medical condition: Artritis Reumatoide _______________________ Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FI (Completed) EE (Completed) HU (Completed) NL (Completed) DE (Completed) GR (Completed) NO (Completed) LT (Completed) CZ (Completed) IT (Completed) AT (Completed) PT (Completed) SK (Completed) GB (GB - no longer in EU/EEA) BE (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005648-93 Sponsor Protocol Number: CD-IA-CAM-3001-1109 Start Date*: 2012-07-19
    Sponsor Name:MedImmune Ltd
    Full Title: An Open-label Extension Study to Evaluate the Long-term Safety of Mavrilimumab in Adult Subjects with Rheumatoid Arthritis
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) HU (Completed) CZ (Completed) DE (Completed) ES (Completed) BG (Completed) GR (Completed) SK (Completed) PT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-005634-19 Sponsor Protocol Number: CD-IA-CAM-3001-1071 Start Date*: 2012-05-30
    Sponsor Name:MedImmune Ltd
    Full Title: A Phase 2b Study to Evaluate the Efficacy and Safety of Mavrilimumab in Subjects with Moderate-to-Severe Rheumatoid Arthritis.
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) EE (Completed) CZ (Completed) ES (Completed) DE (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-020892-22 Sponsor Protocol Number: D4300C00005 Start Date*: 2010-11-23
    Sponsor Name:AstraZeneca AB
    Full Title: A Long-term Extension Study to Assess the Safety and Efficacy of Fostamatinib Disodium (FosD) in the Treatment of Rheumatoid Arthritis
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    16.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) GB (Prematurely Ended) DE (Completed) SK (Prematurely Ended) HU (Prematurely Ended) LV (Prematurely Ended) EE (Prematurely Ended) LT (Prematurely Ended) CZ (Prematurely Ended) PT (Prematurely Ended) ES (Prematurely Ended) BG (Prematurely Ended) IT (Prematurely Ended) NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-000940-32 Sponsor Protocol Number: IM101-365 Start Date*: 2016-04-28
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase III, Multicenter, Open-Label Study to Assess Efficacy, Safety, Pharmacokinetics and Immunogenicity of Abatacept Administered Intravenously in Japanese Children and Adolescents with Active J...
    Medical condition: Juvenile Idiopathic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-001220-38 Sponsor Protocol Number: CAIN457F2208 Start Date*: 2011-07-12
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, 12 week, randomized, double-blind, placebo-controlled biomarker study of secukinumab (AIN457) in rheumatoid arthritis patients followed by an open label extension
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003148-11 Sponsor Protocol Number: MoA-Ustekinumab Start Date*: 2015-01-29
    Sponsor Name:Academic Medical Center
    Full Title: Mechanism of action study of Ustekinumab treatment in psoriatic arthritis: Impact on cellular and molecular pathways of synovial inflammation and tissue remodeling
    Medical condition: psoriatic arthritis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10066579 Progression of psoriatic arthritis LLT
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10066730 Recurrent psoriatic arthritis LLT
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10037160 Psoriatic arthritis LLT
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10003377 Arthropathy psoriatic LLT
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10037161 Psoriatic arthritis aggravated LLT
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10037162 Psoriatic arthropathy PT
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10037163 Psoriatic arthropathies HLT
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10037166 Psoriatic spondylitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002872-95 Sponsor Protocol Number: Start Date*: 2014-09-15
    Sponsor Name:Novartis Pharma S.A.S
    Full Title: A French open-label extension study of canakinumab in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) who participated in the international phase III study CACZ885G2301E1
    Medical condition: Systemic Juvenile Idiopathic Arthritis (SJIA) with active systemic manifestations
    Disease: Version SOC Term Classification Code Term Level
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-003341-18 Sponsor Protocol Number: DSC/11/2357/42 Start Date*: 2011-10-14
    Sponsor Name:Italfarmaco S.p.A.
    Full Title: An Open-Label Extension of the Dose Finding study (DSC/08/2357/36) in patients with polyarticular course Juvenile Idiopathic Arthritis (poly JIA)
    Medical condition: Polyarticular course Juvenile Idiopathic Arthritis (poly JIA)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-001097-25 Sponsor Protocol Number: ML25756 Start Date*: 2011-10-19
    Sponsor Name:Roche Pharma AG
    Full Title: Long-term, interventional, open label extension study evaluating the safety of tocilizumab treatment in patients with polyarticular-course juvenile idiopathic arthritis from Germany who completed t...
    Medical condition: Polyarticular-course juvenile idiopathic arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender:
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-006562-20 Sponsor Protocol Number: JAKIPRA Start Date*: 2022-10-26
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: JAK Inhibition in PReclinical Arthritis
    Medical condition: Preclinical Phase of rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002790-22 Sponsor Protocol Number: EFC13752 Start Date*: 2014-06-02
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: An open-label, randomized, parallel group study assessing the immunogenicity and safety of sarilumab administered as monotherapy in patients with active rheumatoid arthritis
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012759-12 Sponsor Protocol Number: WA19926 Start Date*: 2009-10-14
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A multi-center, randomized, double-blind, parallel group study of the safety, disease remission and prevention of structural joint damage during treatment with tocilizumab (TCZ), as a monotherapy a...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) DE (Completed) ES (Completed) FI (Completed) FR (Completed) PT (Completed) DK (Completed) IE (Completed) GR (Completed) SE (Completed) IT (Completed) HU (Completed) CZ (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2013-000944-25 Sponsor Protocol Number: CAIN457F2302E1 Start Date*: 2013-08-02
    Sponsor Name:Novartis Farma S.p.A.
    Full Title: A three year extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in subjects with active rheumatoid arthritis
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    16.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020065-24 Sponsor Protocol Number: WA25204 Start Date*: 2011-08-15
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A clinical outcomes study to evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) in comparison with etanercept (ETA) on the rate of cardiovascular events in patients with moderate...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) LV (Completed) BE (Completed) AT (Completed) LT (Completed) CZ (Completed) DE (Completed) ES (Completed) NL (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-016266-90 Sponsor Protocol Number: EFC11072 Start Date*: 2011-05-03
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: Estudio aleatorizado, doble-ciego, controlado con placebo, multicéntrico, de dos partes, de búsqueda de dosis y confirmatorio, con un diseño operacionalmente adaptativo que evalúa la eficacia y seg...
    Medical condition: Artritis Reumatoide _____________________________________ Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) FI (Completed) HU (Completed) EE (Completed) DE (Completed) LT (Completed) PT (Completed) NL (Completed) GR (Completed) RO (Completed) AT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002852-26 Sponsor Protocol Number: MS200588-0004 Start Date*: 2016-12-07
    Sponsor Name:Merck KGaA
    Full Title: A multicenter, randomized, double-blind, Phase III trial to evaluate the safety, immunogenicity, and efficacy of MSB11022 compared with Humira® in patients with moderately to severely active rheuma...
    Medical condition: moderately to severely active rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) HU (Completed) DE (Completed) LT (Prematurely Ended) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-004887-39 Sponsor Protocol Number: SB5-G21-RA Start Date*: 2015-08-08
    Sponsor Name:Samsung Bioepis Co., Ltd
    Full Title: An Open-labelled, Single-arm, Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects with Rheumatoid Arthritis
    Medical condition: Subjects with Rheumatoid Arthritis. The intended use of SB5 is rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (JIA), adult Crohn's disease (CD), paediatric CD, ankylosing sp...
    Disease: Version SOC Term Classification Code Term Level
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-001987-12 Sponsor Protocol Number: IRFMN-RA-6453 Start Date*: 2017-08-18
    Sponsor Name:SOCIETA' ITALIANA DI REUMATOLOGIA - SIR
    Full Title: Open-label, randomized controlled trial comparing tocilizumab to anti-TNF treatment and discovery of biomarkers for treatment selection in rheumatoid arthritis patients with inadequate response to ...
    Medical condition: RHEUMATOID ARTHRITIS
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10037738 R arthritis LLT
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039014 Rh arthritis LLT
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10003268 Arthritis rheumatoid LLT
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002275-41 Sponsor Protocol Number: M12-783 Start Date*: 2012-03-15
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Single-Blind Crossover Study of the Safety and Tolerability of Two Adalimumab Formulations in Adult Subjects with Rheumatoid Arthritis.
    Medical condition: Rheumatoid Arthritis.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 09:34:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA